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Abstract
A 72-year-old male presented to the emergency department
with a chief complaint of diarrhea after testing positive for
COVID-19 two days prior; he initially had minimal respiratory
complaints. He was admitted and eventually transferred to
the intensive care unit for acute hypoxic respiratory failure. In
addition to dexamethasone, Remdesivir, and antibiotics, the
patient was treated with Baricitinib. The Food and Drug Administration recently granted this Janus kinase inhibitor Emergency Use Authorization (EUA) to treat hospitalized patients

with COVID-19. He had an extensive and complicated hospital course and had to be placed on mechanical ventilation,
ultimately undergoing tracheostomy. After 78 days of hospitalization, his family withdrew life-sustaining measures, and
the patient died shortly thereafter. This case details the use
of Baricitinib for the treatment of COVID-19 pneumonia and
demonstrates the need for additional studies regarding the
efficacy of this drug.

Introduction

COVID-19 at an outside facility two and seven days
ago, respectively. Two days before presentation, he began having decreased appetite, nausea, diarrhea, and
a mild nonproductive cough. He denied fevers, chills,
chest pain, shortness of breath, or changes to his ability
to taste or smell.

Since the initial reports of SARS-CoV-2 infection, there
have been over 100 million confirmed cases of COVID19.[1] Although many infected with SARS-CoV-2 remain asymptomatic, others can develop severe pneumonia with a fatal illness. Many therapies have been
studied to treat COVID-19. As of January 2021, the
current standard of care for critically ill hospitalized
patients includes dexamethasone and Remdesivir.[2]
The Food and Drug Administration (FDA) recently
granted emergency use authorization for Baricitinib, a
drug typically used to treat rheumatoid arthritis, for the
treatment of COVID-19.[3] This report presents the first
use of Baricitinib at the University of Louisville Hospital to treat COVID-19 in a critically ill patient.

Case Presentation
A 72-year-old male with a history of hypertension and
chronic kidney disease stage 3 presented to the emergency department on December 2, 2020, with a chief
complaint of diarrhea. He reported that before this
presentation, he and his wife were diagnosed with
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Upon arrival to the emergency room, his temperature
was 100.9°F, with all other vitals stable and oxygenation at 95 percent on room air. At this time, he was admitted to the medical floor, where a subsequent chest Xray showed patchy right infrahilar opacities concerning
pneumonia and/or atelectasis (Figure 1a). Routine labs
were notable for a creatinine increased to 1.9 mg/dL
from his baseline of ∼1.4 mg/dL. Other pertinent lab
values in this patient with COVID-19 are included in
Figure 2. Given his clinical stability, antibiotics and
dexamethasone were deferred on admission. However,
the patient spiked fevers up to 103.1°F and had oxygen
saturation to 91 percent shortly after admission. Therefore, on day 2 of hospitalization, he was started on dexamethasone, ceftriaxone, and azithromycin for possible
superimposed bacterial pneumonia. On day 3 of hospitalization, he continued to have oxygen saturations
in the low 90s and required nasal cannula and initia-
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Figure 1. Patient chest X-ray on days 1 and 4 of hospitalization.

a) Hospital day 1: Patchy right infrahilar opacities concerning

b) Hospital day 4: Interval worsening of the bilateral patchy

for pneumonia.

airspace opacities.

tion of remdesivir. On day 4 of hospitalization, he had
acute decompensation from a respiratory standpoint
and was placed on a 15L non-rebreather mask. Arterial
blood gas was obtained at this time, which revealed pH
7.49, pCO2 31, and pO2 38 on 90% FiO2 . Chest x-ray
showed worsening of bilateral patchy airspace opacities (Figure 1b). He was transferred to the ICU, where
he was placed on BiPAP (FiO2 80%) and maintained
oxygen saturations in the upper 90s. However, when
an attempt was made to wean the patient to a highflow nasal cannula (HFNC), he became more hypoxic.
Ceftriaxone and azithromycin were discontinued after
five days of treatment due to a lack of improvement on
antibiotics and low suspicion of a bacterial source.
On day 6 of hospitalization, 4mg oral Baricitinib daily
was started. Additionally, the patient was asked to selfprone while in the ICU. On day 8 of hospitalization,
he completed a 5-day course of remdesivir and underwent numerous transitions between BiPAP and HFNC
for several days. On day 12, a chest x-ray showed a
new focal consolidation in the right upper lobe, which
required him to start cefepime. Given his low lung
reserve and worsening respiratory fatigue, he eventually required mechanical ventilation and was medically
paralyzed on day 13 — the same day that his 10-day
course of dexamethasone was completed. He went on
to develop acute tubular necrosis and became progressively oliguric and azotemic. His creatinine trended
up and peaked at 7.6 mg/dL (Figure 3). On hospital day 16, he was started on continuous renal replacement therapy due to his worsening renal function and
volume overload. Baricitinib was discontinued on the
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same day. Therefore, he only received ten days of Baricitinib therapy rather than the planned 14 days. He
could not be weaned off the ventilator and underwent
placement of a tracheostomy on day 37 of hospitalization.
His subsequent course was complicated by persistent
fevers, worsening hypoxia, shock requiring vasopressors, and ventilator-associated pneumonia due to Serratia marcescens. Overall, the patient spent 78 days in
the hospital and eventually died after the family withdrew life-sustaining measures.

Discussion
Baricitinib is a Janus kinase inhibitor used for the treatment of moderate-to-severe rheumatoid arthritis.[4]
In addition to its role as an immunomodulator, it
is thought to play a role in inhibiting viral entry.[5]
On November 19, 2020, the FDA granted emergency
use authorization of Baricitinib, in combination with
Remdesivir, for hospitalized patients with COVID-19
requiring supplemental oxygen, invasive mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO).[5]
This authorization was primarily based on results
from the Adaptive COVID-19 Treatment Trial (ACTT2) study conducted by the National Institute of Allergy
and Infectious Diseases (NIAID).[6] This study was a
randomized, double-blind, placebo-controlled clinical
trial in hospitalized patients with COVID-19 of varying severity who received Baricitinib plus Remdesivir
2
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Figure 2. Patient laboratory values.
a) Trend of inflammatory markers.

b) Trend of procalcitonin and D-dimer.
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Figure 3. Trend of creatinine.

or placebo plus Remdesivir. The treatment group received oral Baricitinib 4 mg once daily for 14 days or
until hospital discharge plus standard-dose Remdesivir
for ten days or until hospital discharge. The primary
endpoint was time to recovery within 29 days. Recovery was defined as the first day on which one of the
following three categories was met: The patient is no
longer hospitalized, and without limitations on activities, the patient is no longer hospitalized has some limitations on activities and/or requiring home oxygen, the
patient is hospitalized but not requiring supplemental
oxygen and no longer requiring ongoing medical care.
The median time to recovery from COVID-19 was
seven days for those treated with Baricitinib plus
Remdesivir, and eight days for those given placebo
plus Remdesivir [hazard ratio: 1.16 (95% confidence
interval (CI) 1.01, 1.32); P=0.03].[6] The odds of clinical improvement at day 15 were also higher in the
treatment group versus placebo [odds ratio: 1.26 (95%
CI 1.01, 1.57); P=0.044]. Additionally, the proportion of patients who died progressed to noninvasive
ventilation/high-flow oxygen or progressed to invasive mechanical ventilation by day 29 was lower in the
Baricitinib group (23%) versus placebo (28%) [odds ratio: 0.74 (95% CI 0.56, 0.99); P=0.039]. The overall 28day mortality was 5.1% for the treatment group and
7.8% for the placebo group [hazard ratio for death, 0.65
(95% CI 0.39, 1.09)]. Given these findings, the FDA
granted emergency use authorization for Baricitinib in
combination with Remdesivir in hopes of offering an
effective treatment option to those hospitalized with
COVID-19.
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Baricitinib has not yet received FDA approval to be
used as a monotherapy for infection with SARS-CoV2. However, many studies have been conducted to
show its efficacy as a monotherapy.[7] Currently, there
is no consensus of eligibility criteria of study participants due to the widely varying conditions in which
these clinical trials are being conducted.[8] Furthermore, while the previous results demonstrate that the
addition of Baricitinib to Remdesivir improves the time
to recovery, no data currently exist comparing the addition of Baricitinib to Remdesivir versus the addition
of dexamethasone. Large, randomized trials, such as
RECOVERY, have shown evidence of a benefit with the
addition of dexamethasone to Remdesivir.[9] However,
among the 223 patients in ACTT-2 who were also on
glucocorticoids during the trial, there was no detected
difference in recovery time with the addition of Baricitinib.[6] Currently, the fourth iteration of the Adaptive
COVID-19 Treatment Trial (ACTT-4) is underway.[10]
This study will directly compare the effects of Baricitinib versus dexamethasone and determine the clinical
efficacy of Remdesivir plus Baricitinib versus Remdesivir plus dexamethasone as measured by mechanical
ventilation–free survival at day 29.[10] The results of
this study will offer clinicians guidance on selecting
various treatment options currently available for hospitalized patients with COVID-19.
Some possible side effects in patients with COVID19 treated with Baricitinib include venous thrombosis,
pulmonary embolism, hypersensitivity reactions, and
serious infections.[3] However, in ACTT-2, major adverse events were less frequent in the Baricitinib arm
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(16.0%) than in the placebo arm (21.0%) [difference 5.0% (95% CI -9.8, -0.3); P=0.03].[6] Additionally, there
was a lower rate of new infections in the Baricitinib
arm (5.9% vs 11.2%) [difference -5.3% (95% CI -8.7, 1.9); P=0.003]. According to the authors of ACTT2, the consistently lower incidence of adverse events
with Baricitinib may be related to its role in reducing inflammatory-mediated lung injury and improving
lymphocyte counts. Moreover, its antiviral properties
and the associated shorter recovery time with faster
clinical improvement could have reduced the risk of
nosocomial infection.
There are no known contraindications for the use of
Baricitinib.[11] However, all patients should have laboratory values (i.e., estimated glomerular filtration rate,
liver enzymes, complete blood count) evaluated at
baseline and thereafter. Dose adjustments may be necessary should abnormal renal, hepatic, or hematologic
lab values arise. Baricitinib is not indicated for patients
on dialysis or those with end-stage renal disease (eGFR
<15 mL/min) and those with acute kidney injury, as
there are limited data on the use of the drug in patients with severe renal impairment. Additionally, it
is not recommended for patients with active tuberculosis. Baricitinib should be used with caution in pregnant patients, although insufficient data suggests a risk
of miscarriage or congenital disabilities. The use of live
vaccines should be avoided with Baricitinib. Finally, it
is recommended that patients taking strong OAT3 inhibitors (i.e., probenecid) reduce the dose of the OAT3
inhibitor to avoid excessive Baricitinib exposure.
In the present case, the patient’s lengthy and complicated hospital course makes it difficult to ascertain the
role Baricitinib played in treating his COVID-19 infec-
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tion. However, he would not have met any of the
29-day outcomes in the ACTT-2 trial. Several factors
need to be taken into consideration when reviewing
this case. Firstly, this patient was treated only ten days
of Baricitinib therapy compared to the recommended
14 days due to his declining renal function. It is unclear
whether this shorter course played a role in his lack of
clinical response to treatment and eventual death. Secondly, this patient was treated with both Baricitinib and
dexamethasone in addition to Remdesivir. It can be
challenging to discern the benefits and harms of Baricitinib and systemic corticosteroids when given simultaneously. Since both drugs are immunosuppressants,
there is a theoretical additive risk of infection. While
this patient developed a hospital-acquired bacterial infection after initially contracting COVID-19, it remains
unknown whether this was due to immunosuppression
or due to other causes, as his Serratia pneumonia developed days after discontinuation of Baricitinib. Following the FDA’s emergency use authorization of Baricitinib, the National Institutes of Health COVID-19 Treatment Guidelines Panel recommended using Baricitinib
with Remdesivir in cases where dexamethasone cannot
be used.[12] More data are needed to clarify the role
of Baricitinib in combination with corticosteroids. Still,
trials such as ACTT-4 will provide much-needed information to guide the selection of the initial immunosuppressive agent.
In conclusion, the emergency use of Baricitinib in combination with Remdesivir remains an alternative option
in treating hospitalized COVID-19 patients. However,
Baricitinib had no apparent benefit in this case, as the
patient continued to deteriorate even after its initiation
clinically. Therefore, more studies are needed to determine its safety and effectiveness.
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